Cdkn1c (p57Kip2) is the major regulator of embryonic growth within its imprinted domain on mouse distal chromosome 7
BMC Developmental Biology volume 7, Article number: 53 (2007)
Cdkn1c encodes an embryonic cyclin-dependant kinase inhibitor that acts to negatively regulate cell proliferation and, in some tissues, to actively direct differentiation. This gene, which is an imprinted gene expressed only from the maternal allele, lies within a complex region on mouse distal chromosome 7, called the IC2 domain, which contains several other imprinted genes. Studies on mouse embryos suggest a key role for genomic imprinting in regulating embryonic growth and this has led to the proposal that imprinting evolved as a consequence of the mismatched contribution of parental resources in mammals.
In this study, we characterised the phenotype of mice carrying different copy number integrations of a bacterial artificial chromosome spanning Cdkn1c. Excess Cdkn1c resulted in embryonic growth retardation that was dosage-dependent and also responsive to the genetic background. Two-fold expression of Cdkn1c in a subset of tissues caused a 10–30% reduction in embryonic weight, embryonic lethality and was associated with a reduction in the expression of the potent, non-imprinted embryonic growth factor, Igf1. Conversely, loss of expression of Cdkn1c resulted in embryos that were 11% heavier with a two-fold increase in Igf1.
We have shown that embryonic growth in mice is exquisitely sensitive to the precise dosage of Cdkn1c. Cdkn1c is a maternally expressed gene and our findings support the prediction of the parental conflict hypothesis that that the paternal genome silences genes that have an inhibitory role in embryonic growth. Within the IC2 imprinted domain, Cdkn1c encodes the major regulator of embryonic growth and we propose that Cdkn1c was the focal point of the selective pressure for imprinting of this domain.
Genomic imprinting is an unusual epigenetic phenomenon that results in the absence of expression of one copy of an autosomal gene. This allele-specific expression is initiated by events that take place within the male and female germ line during gametogenesis . The parental alleles acquire an epigenetic signature that is recognised in the somatic cell and, as a result, there is permanent and heritable silencing of one parental allele. Studies on imprinted genes in mice suggest a general role for imprinting in the regulation of embryonic growth [2–8]. Two key genes that regulate embryonic growth, insulin-like growth factor 2 (Igf2) and insulin-like growth factor receptor 2 (M6P/Igf2r) are oppositely imprinted. In mice, insulin-like growth factor 1 (Igf1) and the imprinted Igf2 are thought to be the two major growth signalling molecules. These factors work in combination with at least three receptors, the insulin receptor (Insr), insulin-like growth factor receptor 1 (Igf1r) and the imprinted Igf2r to exert local and systemic effects on growth .
Single genetic or epigenetic changes can deregulate the function of an imprinted gene and they are particularly vulnerable targets for numerous human pathologies (recently reviewed in [9–11]. Since the cost of adopting monoallellic gene expression to an individual is clearly quite high, there must be a compelling reason for mammals to imprint their genes. The most widely accepted model that has been proposed to explain the evolution of genomic imprinting is known as the parental conflict hypothesis [12, 13]. This hypothesis focuses on the asymmetry in mammals between parental contributions to the developing fetus. Although larger offspring are thought to be of benefit to both parents, in females there must be a balance between the fitness of the offspring and survival of the mother. Genomic imprinting of the paternal genome may have evolved to promote growth of the fetus while imprinting of the female genome occurred to counteract the effects of the paternal genome in order for the mother to survive and produce more offspring. However, deficiency in expression of an imprinted gene does not always lead to an embryonic growth phenotype . Careful studies have revealed effects on mammalian behaviour for several genes [6, 7, 15–19] which suggests that the role of genomic imprinting may be more complex or that some genes are imprinted by virtue of their proximity to imprinting centres (ICs).
While studies on loss of function are important for our understanding of gene function by itself, over expression studies may provide more unequivocal information on the significance of imprinting of a particular gene. Biallelic gene expression can be studied in mice with uniparental disomy [20–22] or in mice where a targeted deletion of an imprinting centre (IC) has released genes from imprinting [23–25]. These studies generally involve multiple genes and, in regions where there are both paternally and maternally expressed genes, can also involve loss of expression. The primary advantage of using large genomic clones to analyse imprinted genes is that the exact nature and number of genes is defined by the transgenic sequence, there is no loss of expression and the genes are expressed from their endogenous promoters at the appropriate level and time, predominantly without being affected by the site of integration .
Cdkn1c, also known as p57Kip2, encodes a maternally expressed, cyclin-dependant kinase inhibitor (CDKi) [27–30]. Expression is tissue-specific and at high levels in cells entering mitotic arrest [27, 28]. Loss of expression of Cdkn1c through maternal inheritance of a targeted deletion results in severe developmental abnormalities [31, 32], similar to that seen in humans with loss of CDKN1C in Beckwith-Wiedemann syndrome (BWS) [33–37]. As with all CDKis, excess Cdkn1c induces cell cycle arrest [27, 28]. Forced expression of Cdkn1c in retinal cultures leads to premature cell cycle exit  and Cdkn1c co-expression with Nurr1 promotes maturation of a midbrain dopaminergic neuronal cell line  demonstrating a role for Cdkn1c in both cell cycle regulation and cellular differentiation.
The Cdkn1c gene is located within a large cluster of imprinted genes on mouse distal chromosome 7 . Maternal disomy of this region results in embryonic and extra embryonic growth retardation and embryonic lethality . There are two ICs within this domain controlling two mechanistically distinct sub domains [25, 40, 41]. Imprinting of Cdkn1c is achieved through IC2, also known as KvDMR1  and mice paternally inheriting a targeted deletion of the KvDMR1 locus show growth retardation. Growth retardation is also associated with maternal transmission of an 800 kb YAC transgene spanning eleven genes from Nap1l4 to Th but excluding the IC1 domain . All these studies involve multiple imprinted genes and dissecting which gene is responsible for a particular phenotype is not straightforward. Nonetheless, the proportionality of the growth retardation in all these mice suggests a systemic effect on growth. Since Igf2, which encodes a potent embryonic mitogen, is unaffected by the KvDMR1 deletion, one or more of the other deregulated genes may play a novel role in regulating whole organism growth.
In this study, we characterised the phenotype of mice carrying different copy number integrations of a bacterial artificial chromosome spanning Cdkn1c. We show copy-number dependent embryonic growth retardation that is most severe on the 129/Sv genetic background. By using a modified BAC transgene spanning the same genomic region but with an inactivated Cdkn1c, we can assign the embryonic phenotype to Cdkn1c alone. These data indicate that Cdkn1c encodes the most important regulator of embryonic growth within the IC2 domain on mouse distal chromosome 7.
Excess Cdkn1ccauses embryonic lethality
Following on from our previous work on studying the mechanism of imprinting of Cdkn1c [43, 44], we investigated the consequences of over expressing Cdkn1c in vivo on development. We generated transgenic mice carrying an 85 kb bacterial artificial chromosome (BAC) spanning the Cdkn1c locus  (Figure 1A). When ES cell lines with low copy number insertions of this transgene (1–4) were aggregated with MF1 morulae, there was a high incidence of perinatal loss (Table 1). No live born chimeras were obtained for high copy lines (Table 1). When surviving chimeras from four independent lines were crossed to out bred MF1 females, transgenic offspring were detected at the expected frequency (Table 2). When these same chimeras were crossed with 129/Sv females, transgenics were recovered at low frequency in a single copy line (1/33) and not at all in three other lines containing 2–4 copies of the transgene (Table 2). We examined litters at earlier time points and dying transgenic embryos were observed at varying stages, some as early as E10.5 (Line 5B6, four copies).
We have previously shown that the transgenic Cdkn1c transcript is expressed only in a subset of tissues from this 85 kb BAC at E13.5 by in situ hybridisation . Immunohistochemistry with a Cdkn1c-specific antibody showed a similarly restricted distribution of the Cdkn1c protein at E12.5, mainly to neural tissues (Figure 1B). Real Time RT-PCR measurements of the Cdkn1c transcript revealed an increase in the overall expression of 1.36-fold in whole embryos carrying a single copy of the BAC transgene (line 5D3) and 1.75-fold in embryos carrying two copies (line 5A4) at E13.5 (Figure 1C). This reflects the restricted expression from the BAC which we confirmed in E12.5 embryos by comparing the levels of expression in the head versus the body in the single copy line (Figure 1D). This is consistent with expression from the single-copy transgene at levels similar to the endogenous gene in neural tissues where we know the transgenic Cdkn1c to be expressed. We were not able to detect over expression of Cdkn1c in the body. We know from our in situ data, immunohistochemistry and a reporter transgene  that Cdkn1c is expression from the BAC in only a subset of the non-neuronal tissues where endogenous Cdkn1c is expressed such as the lung endothelium and the developing kidney tubules. The endogenous Cdkn1c is expressed most strongly in skeletal muscle and cartilage, where we do not see expression from our transgene. This very strong expression maybe masking the more subtle changes in tissues where there is a relatively lower level expression of Cdkn1c. These data are consistent with copy-number dependent expression of Cdkn1c from the BAC in a subset of tissues.
Growth is exquisitely sensitive to the dosage of Cdkn1c
The transgenic offspring from the cross between the chimeric males and the MF1 females were noticeably smaller than their wild type littermates. The degree of growth retardation increased with increasing copy number of the transgene and persisted after weaning (Figure 2A). Persistent growth retardation was also observed when the single copy transgene was bred onto the C57/BL6 background for three generation (Fig 2B).
The degree of growth retardation also varied with strain background. Transgenic F1 males (50%:50%; 129/Sv:MF1) from a single copy line, 5D3, were 11.3% smaller at three weeks but when these males were crossed with 129/Sv females, the transgenic F2 male offspring (75%:25%; 129/Sv:MF1) were 29% smaller than their non-transgenic litter mates (Figure 2C, two tail student t-Test: P = 0.017). Generation 3 C57B/L6 males showed an intermediate phenotype of 20% growth retardation at this time point (Figure 2C, P = 0.02). In contrast the lethality associated with an increasing contribution of the 129/Sv genetic background, no evidence of lethality was associated with the presence of a single copy of the transgene on the C57BL/6 background (data not shown).
We examined the age at which males acquired sexual maturity as judged by the timing of their first mating. Despite their small size, transgenic male adult mice reached sexual maturity at the same time as wild type littermates and were fertile (Table 3). The majority of females also reached sexual maturity at a similar age to their wild type littermates but there was one female that had a litter late and two that did not have litters during the time of observation (Table 3). Those that had litters were able to nest and feed their offspring. It should be noted that there is variable fertility in the rare surviving females that are deficient in Cdkn1c . The Cdkn1c-deficient mice also show a severe postnatal growth defect. This is consistent with a defect in pituitary development. It is possible that, given the expression of Cdkn1c from our transgene in the pituitary, further studies on transgenics animals with a higher 129/Sv genetic contribution might reveal an endocrine defect in adults and this is under investigation.
Cdkn1c is a cell cycle inhibitor that acts intrinsically to limit cell proliferation. We would expect that the tissues in which there was excess Cdkn1c would be disproportionately smaller than those without. We examined the weights of organs with no excess Cdkn1c (heart, spleen, testes and liver) and those in which there had been excess embryonic Cdkn1c (kidney and brain, Figure 2D) in eight-week old males. There were no significant difference in comparison to body weight (P = 0.12–0.87) between wild type and transgenic males. Growth retardation induced by the presence of a single copy BAC was not restricted to the tissues in which the transgenic Cdkn1c was expressed.
The transgenic embryos were small but similar in appearance to wild type embryos (Figure 3A) in all four lines. At E13.5, transgenic embryos from line 5D3 (single copy) on a mixed MF1:129/Sv background are 14% smaller than wild type (Figure 3B; P = 7.2 × 10-7). This phenotype is comparable to that reported for the KvDMR1 deletion and the 800 kb YAC where several additional genes are also over expressed [25, 42]. In contrast, embryos null for Cdkn1c were 11% heavier wild type embryos at E13.5 (Figure 3D, P = 0.008).
Phenotype is due to excess Cdkn1c
The transgene spans two other genes, Phlda2 (also known as Ipl or Tssc3)  and Slc22a18 (also known as Impt1 or Tssc5) . The growth retardation and embryonic lethality could be a consequence of over expression of any one of these genes. To test this possibility, we examined the transgenic line, 10–15 (Cdkn1c-βgeo). This line contains three copies of the same BAC but the Cdkn1c gene on the BAC has been inactivated by the insertion of a reporter gene (Figure 1A) . In these mice, Cdkn1c is not over expressed in the embryo (Figure 1C). Phlda2 and Slc22a18, which are predominantly expressed in extra embryonic tissues [45, 47], are highly over expressed in the placenta  but not detectable in the embryo at E13.5 (data not shown).
No embryonic lethality was observed when we first generated this line or when we backcrossed the mice for six generations onto the 129/Sv background (Table 2). This contrasts with almost complete loss of transgenic animals (1/34 transgenic/wild type) after crossing 5D3 F1 males (50:50; 129/Sv × MF1) onto the 129/Sv background for three generations (>93% 129/Sv). There was no significant difference in weights between males from line 10–15 (Cdkn1c-βgeo) and wild type littermates at three weeks (Figure 2B, P = 0.24) and embryos from line 10–15 (Cdkn1c-βgeo) are not significantly different to their wild type counter parts (P = 0.24) at E13.5 (Figure 3C). This line was generated by pronuclear injection and it was possible that we selected against any transgenic lines showing an adverse phenotype. Therefore, we also examined embryos at E13.5 after a second round of pronuclear injection. Seven embryos representing independent integration events were identified. No significant difference in embryonic size was noted (data not shown).
Placental insufficiency can also cause embryonic growth retardation in mice as illustrated by the placental specific Igf2 knock out . Both the unmodified and modified BAC transgenic lines have a placental defect due to excess Phlda2 and/or Slc22a18 ( and our unpublished data). In the absence of over expression of Cdkn1c in line 10–15 (Cdkn1c-βgeo), this placental defect leads to a slow down in embryonic growth detectable at E16.5 . In the lines with excess Cdkn1c, we observe embryonic growth retardation three days earlier, at E13.5. Our control line 10–15 (Cdkn1c-βgeo) embryos are of normal weight at E13.5 (Figure 3C). Therefore, this earlier defect in embryonic growth is due to excess Cdkn1c and not due to the placental insufficiency shared by both lines. Furthermore, a key characteristic of IUGR due to placental insufficiency in mice is postnatal "catch up" growth . Our mice do not recover their growth potential after birth (Figure 2A). Even at one year, they are noticeably smaller than their wild type siblings (data not shown).
We can conclude that excess Cdkn1c in the embryo causes sustained growth retardation and, on the 129/Sv genetic background, also causes embryonic lethality.
Igf1 expression is reduced as a consequence of increased Cdkn1clevels
Cdkn1c acts intrinsically to regulate cell proliferation and, in some tissues, also directs differentiation. However, growth retardation was not limited to the tissues in which there was an embryonic excess Cdkn1c. One possible explanation was that excess Cdkn1c altered the expression level of one of the key embryonic growth regulatory genes which would then have an extrinsic effect on growth. We used quantitative Real Time RT-PCR to measure the transcript levels of several genes known to regulate embryonic growth. At E11.5 we identified a reduction in Igf1 in our two-copy line but not in our single-copy line. Igf1 was reduced in both the single-copy and the two-copy transgenic lines at E13.5 when there was obvious growth retardation (Figure 4A). Igf2 levels were slightly raised at E11.5 in both lines and reduced at E13.5 only in the two-copy line (Figure 4B).
In the single copy line, we only detected changes in Igf1 at E13.5, when the growth retardation phenotype was well established. In order to detect more subtle changes in gene expression at an earlier time point in this line, we examined Igf1 and Igf2 levels in RNA prepared separately from the head and in the body of E12.5 embryos. Cdkn1c expression from our transgene was predominantly in neural tissues and we reasoned that we would be more likely to detect a change in expression in material where this tissue predominates. When we examined the transgenic embryos, we found that the level of Igf1 in the head was dramatically reduced to 40% of the wild type level (Figure 4C). In the body, where we have minimal over expression of Cdkn1c, Igf1 levels were not significantly changed from normal. The central nervous system is a major site for expression of Igf1 [50, 51]. Consistent with this observation, we found that, in wild type embryos, there was 9.5-fold more Igf1 RNA in the head than in the body at E12.5 (data not shown). Igf2 levels were raised in the head by two-fold and reduced in the body by 50%. Since the body (mesodermal tissues) is the primary source of Igf2 , the overall change in expression in the transgenic embryos was not significant.
To provide further data to support a role for Igf1 in the growth phenotype, we examined Igf1 and Igf2 levels in RNA prepared from the heads and bodies of embryos null for Cdkn1c at E12.5. We again found changes in the level of expression of Igf1 with a three-fold increase in Igf1 expression levels in the head and difference in expression in the body (Figure 4C). Igf2 levels were relatively unchanged in both samples (Figure 4D).
We have found an inverse correlation between the level of expression of Cdkn1c and the level of expression of the potent growth factor Igf1. These data are consistent with a role for this growth factor in our growth phenotype. Igf1 levels are linked, either directly or indirectly, to level of expression of Cdkn1c and growth is either retarded or enhanced as a consequence.
We have shown that Cdkn1c acts as a true rheostat for embryonic growth, with loss of expression after gene deletion leading to overgrowth and over expression of Cdkn1c causing growth retardation.
Embryonic growth is exquisitely sensitive to the dosage of Cdkn1c
Excess expression of Cdkn1c from a single copy BAC transgene resulted in decreased growth of embryos from at least E13.5 with no catch-up growth after birth. Furthermore, as the level of excess Cdkn1c increased, the size of the animals decreased. Initial reports for the phenotype of Cdkn1c null mice did not reveal a clear affect on growth at birth [31, 32]. However, we found that loss of Cdkn1c was associated with embryonic overgrowth earlier in development, at E13.5. Therefore, Cdkn1c acts as a true rheostat for embryonic growth.
Cdkn1cis the most important regulator of embryonic growth within the IC2 domain
Studies on mono-parental embryos and embryos with paternal or maternal disomy of specific chromosomal regions revealed a key role for imprinted genes in regulating embryonic growth. These studies invariably involved both loss of expression and excess expression of multiple genes and the identification of the target for imprinting of the locus is difficult. Embryos with maternal disomy of mouse distal chromosome 7 showed embryonic and extra embryonic growth retardation and embryonic lethality  with loss of expression of Igf2 and Ins2 and excess expression of a number of genes presumed to include Cdkn1c, Ascl2 and Phlda2 (summarised in Figure 5). Paternal inheritance of a targeted deletion of the KvDMR1, which resulted in loss of imprinting of only the IC2 domain, resulted in a slightly less severe growth retardation  similar to maternal inheritance of the 800 kb YAC spanning all the genes within this domain . Our unmodified BAC, which spans only three of these genes, also caused embryonic growth retardation. The modified BAC, which drives excess Phlda2 and Slc22a18 but not excess Cdkn1c, did not. Therefore, Cdkn1c is the only gene in this region that has been shown to have a major role in regulating embryonic growth.
Embryonic lethality in embryos with maternal disomy of the distal 7 domain may be due to excess Cdkn1c
There are differences in survival between embryos with maternal disomy of distal chromosome 7 and those with paternal inheritance of the KvDMR1 deletion. This could be interpreted to indicate that the embryonic lethality in the mice with maternal disomy of distal 7 was due to loss of Igf2 and/or Ins2. However, embryonic lethality was not been reported for loss of Igf2  or Ins2  alone. Although lethality could be due to a combination of loss of Igf2 with excess Cdkn1c, we have observed embryonic lethality associated with excess Cdkn1c and normal Igf2 levels on the 129/Sv genetic background.
Altered expression of Igf1 in response to changes in the dosage of Cdkn1c
Our data showed that increasing expression levels of Cdkn1c were associated with a decrease in the size of the embryo, starting prior to E13.5. As the level of Cdkn1c increased, we found a consistent decrease in the transcript level of the potent embryonic growth factor, Igf1, which was detectable as early as E11.5 in our two-copy line. Conversely, loss of expression of Cdkn1c was associated with a reciprocal phenotype with the null embryos being 11% heavier than wild type embryos at E13.5 with a three-fold increase in Igf1 at E12.5. Complete loss of Igf1 results in embryonic growth retardation from E13.5 [53, 54]. Similar to our 5D3 mice, Igf1 heterozygotes are 10–20% smaller at birth and remain this small as adults . Although no significance size difference was reported at E13.5 in the Igf1 heterozygotes, genetic modifiers may provide an explanation for this discrepancy since our preliminary data suggest a weaker growth retardation phenotype in the C57BL/6 background on which the Igf1 studies have all been performed.
We also observed disturbances in the level of expression of a second key growth factor transcript, Igf2. However, this was only in the Cdkn1c overexpressing mice and not in the Cdkn1c null mice. Also, we have some limited data from genetic crosses with mice over expressing Igf2  that do not support a major role for this growth factor in our phenotype. It is therefore probable that reduced expression of Igf1 was responsible for growth retardation in the presence of excess Cdkn1c. This would also provide an explanation for why growth retardation was not restricted to the tissues in which there was excess Cdkn1c since Igf1 acts extrinsically to regulate growth. It will be possible to test this in genetic crosses when mice over expressing Igf1 from an endogenous promoter become available.
There are a number of ways in which the cell cycle inhibitor, Cdkn1c, could act on Igf1. Although we cannot exclude a direct role for Cdkn1c in regulating the expression of the Igf1 gene, it seems more plausible that the cell cycle inhibitor acts indirectly, for example by reducing the proliferative potential of the cells in which Igf1 is expressed or by altering the differentiation program of a particular cell type expressing the growth factor.
While it has been known for some time that imprinting acts directly to regulate embryonic growth via the epigenetic modification of key genes, our data suggests that imprinting can also act indirectly to regulate the levels of non-imprinted embryonic growth factors. This further highlights the complexity and the importance of genomic imprinting in mammalian growth and development.
Imprinting of Cdkn1ccomes at a high cost
Loss of expression of this gene is perinatal lethal in mice and linked to BWS in humans [33–37]. We have shown that excess Cdkn1c can be equally detrimental to development in mice and there is some evidence for this in humans . Given the increased frequency of intrauterine growth retardation in babies conceived after assisted reproductive technologies conceptions [57–59] and a prevalence of imprinting mutations in these children [60–63], excess CDKN1C may be an important factor in IUGR in humans which should be explored further.
Imprinting of Cdkn1cmay have played a role in the transition towards increased maternal investment in embryonic growth in placental mammals
The parental conflict hypothesis predicts that over expression of a gene expressed only from the maternal genome should limit embryonic growth. We have presented the first compelling evidence that overexpression of Cdkn1c alone causes growth retardation and therefore the parental conflict hypothesis holds true for this gene. Our work may also provide further clues to the evolutionary consequence of imprinting this important gene. Imprinting has for some time been thought to have emerged prior to the divergence of marsupials from eutherians [64–66]. However, unlike Igf2, Cdkn1c is not imprinted in marsupials . Therefore, the IC1 domain, containing the potent growth factor gene, Igf2, acquired an imprint prior to the divergence of marsupials and eutherians and the IC2 domain, containing Cdkn1c, became imprinted after this divergence. It may be significant that one key difference between marsupials and eutherians is the size and maturity of the offspring at birth and this correlates with the role that we have identified for Cdkn1c in regulating embryonic growth.
By using different copy number transgenes and mice carrying a targeted deletion of Cdkn1c, we have shown that embryonic growth is exquisitely sensitive to the dosage of Cdkn1c. Since Cdkn1c encodes the major regulator of embryonic growth within the IC2 imprinted domain, we propose that Cdkn1c was the focal point of the selective pressure for imprinting of this domain. Cdkn1c is a maternally expressed gene and our findings support the prediction of the parental conflict hypothesis that that the paternal genome will silence genes that have an inhibitory role in embryonic growth. Furthermore, since Cdkn1c acquired its imprinted status after marsupials diverged from placental mammals, our data would support a role for the change in dosage of Cdkn1c gene in the relative increase size of the embryo in eutherians.
All animal studies and breeding was approved by the Universities of Cambridge and Cardiff ethical committees and performed under a UK Home Office project licenses. Inbred 129/Sv and C57BL/6 and out bred MF1 mice were maintained at the Gurdon Institute, Cambridge, UK and Cardiff School of Biosciences. Additional 129/Sv mice were purchased from B+K Universal. Transgenic lines carrying the 85 kb bacterial artificial chromosome were described previously [44, 68]. Essentially, ES cell lines were made by co-electroporation of the linearised BAC with a linearised pgk-neomycin construct and selecting for neomycin positive colonies. Genomic DNA from these colonies was analysed by Southern blotting. Intactness and copy number of the BAC integrations was determined by probing the membrane first with the complete 85 kb BAC (after blocking repeats with total mouse genomic DNA) and then with a single copy probe to Neuronatin . Lines carrying 1–8 copies of the BAC were co-cultured with MF1 morulae to generate chimaeric animals. The lines were maintained on a mixed 129/Sv × MF1 background. F1 5D3 (50%:50%; 129/Sv × MF1) denotes animals that have an equal contribution of MF1 and 129/Sv from a cross between a male chimera and a MF1 female, F2 5D3 (75%:25%; 129/Sv × MF1) denotes animals that have a greater contribution of 129/Sv obtained by crossing a F1 5D3 (50%:50%; 129/Sv × MF1) male with a 129/Sv female. Animals were genotyped by PCR using primers that identified the pBeloBAC vector sequence (R85: 5'-attctgcttacacacgatgc-3' and R86: 5'-ttccgcagaggtcaatcc-3'). Generation of line 10–15, which contains the modified BAC transgene with an inactivated Cdkn1c gene (Cdkn1c-βgeo), was previously described . These mice were maintained on a 129/Sv background as were mice carrying a targeted allele of Cdkn1c . All mice were tailed between P7 and P14 and genomic DNA for genotyping was prepared as described .
Sexual maturity was determined by daily checking for plugs and the appearance of a litter.
Postnatal weights of males were taken at weekly intervals for one to eight weeks. At 8–10 weeks, males were killed by cervical dislocation. Organs were dissected and kept frozen on dry ice before weights were obtained. Embryonic weights were taken 11, 12 or 13 days after a discernable plug, at E11.5, 12.5 or 13.5. Embryos were stored in RNAlater (Sigma) while genotyping data was obtained from yolk sac DNA.
Statistical significance (Probability values) was determined using the Student's t-Test (two tailed distribution and two sample unequal variance). The significance in the difference in observed over the expected appearance of a particular genotype was determined using the Chi-squared Test.
Quantitative RNA analysis
Total RNA was prepared from embryos using TRI Reagent (Sigma). cDNA was prepared using M-MuLV reverse transcriptase (Roche) with random hexamers under the manufacturers conditions. 20 μl cDNA was diluted five-fold in 10 mM Tris.HCl (pH 7.5) and stored at -20°C. For the quantitative PCR, primers were designed to amplify across introns for all the genes using the Primer3 program  unless otherwise stated. Quantitative RT-PCR was performed in duplicate on two independent samples and on two separate occasions on diluted RT+ and RT- material prepared for wild type and transgenic embryos using DyNAmo HS SYBR Green qPCR kit (Finnzymes), GRI 96 PCR detection plates and ABsolute QPCR seal (ABgene) and detected using the Chromo 4 Four-Color Real Time detector (MJ Research). Conditions for amplification: 15 minutes at 95°C (to release polymerase) followed by 40 cycles of 30 seconds at 95°C and 1 minute at 63°C (anneal and extension). 1 μl of diluted cDNA was amplified in a total sample volume of 25 μl with 25 pmoles of each primer. Primers were 5'-agagaactgcgcaggagaac-3' and 5'-tctggccgttagcctctaaa-3' for Cdkn1c, 5'-ggcattgtggatgagtgttg-3' and 5'-tctcctttgcagcttcgttt-3' for Igf1, 5'-gtcgatgttggtgcttctca-3' and 5'-aagcagcactcttccacgat-3' for Igf2 and 5'-cgctgagccagtcagtgtag-3' for 18S. Gapdh and Beta-actin primers were as previously described [72, 73].
E12.5 embryos were fixed in pre-cooled Carnoys (60% ethanol, 30% chloroform, and 10% glacial acetic acid) for 25 min at 4°C, then washed three times for 2 min in 96% ethanol, then 100% ethanol for 2 and 7 min, respectively. Embryos were then cleared in 1:1 ethanol/chloroform (V/V) for 10 min and chloroform for 10 min, then 1hr. Embryos were then impregnated in three changes of 56–58°C melting point paraffin wax (Sigma-Aldrich) for 30 min each at 65°C and embedded. 10 μm sections were dewaxed in xylene and rehydrated through a series of graded ethanol. Washes in PBS with 0.02% Tween 20 were carried out between each subsequent step. Endogenous peroxidases were quenched by incubation in 3% hydrogen peroxide in water for 5 min, then 0.5% hydrogen peroxide in methanol for 1 hr. Sections were blocked in 2.5% horse blocking serum (RTU VECTASTAIN universal quick kit, Vector Labs) for 1 hr. Goat anti-CDKN1C primary antibody M-20 (SC-1039, Santa Cruz) was diluted 1/50 in 0.04% horse blocking serum and incubated at 4°C overnight. Primary antibody was removed and secondary antibody and streptavidin/peroxidase steps were carried out as per manufacturers instructions (RTU VECTASTAIN universal quick kit, Vector Labs). Sigma Fast DAB substrate system was used to visualise staining. Sections were counterstained with Gills III hematoxylin for 1 min then destained for 1 min with acid/alcohol solution (0.5% HCl, 70% ethanol). Sections were dehydrated through a series of graded ethanol and washed in xylene before mounting with DPX mounting medium.
Bacterial Artificial Chromosome
Polymerase Chain Reaction
Yeast Artificial Chromosome
Surani MA: Imprinting and the initiation of gene silencing in the germ line. Cell. 1998, 93 (3): 309-312. 10.1016/S0092-8674(00)81156-3.
DeChiara TM, Robertson EJ, Efstratiadis A: Parental imprinting of the mouse insulin-like growth factor II gene. Cell. 1991, 64: 849-859. 10.1016/0092-8674(91)90513-X.
Efstratiadis A: Genetics of mouse growth. Int J Dev Biol. 1998, 42 (7): 955-976.
Guillemot F, Caspary T, Tilghman SM, Copeland NG, Gilbert DJ, Jenkins NA, Anderson DJ, Joyner AL, Rossant J, Nagy A: Genomic imprinting of Mash2, a mouse gene required for trophoblast development. Nature Genetics. 1995, 9: 235-242. 10.1038/ng0395-235.
Frank D, Fortino W, Clark L, Musalo R, Wang W, Saxena A, Li CM, Reik W, Ludwig T, Tycko B: Placental overgrowth in mice lacking the imprinted gene Ipl. Proc Natl Acad Sci U S A. 2002, 99 (11): 7490-7495. 10.1073/pnas.122039999.
Lefebvre L, Viville S, Barton SC, Ishino F, Keverne EB, Surani MA: Abnormal maternal behaviour and growth retardation associated with loss of the imprinted gene Mest [see comments]. Nat Genet. 1998, 20 (2): 163-169. 10.1038/2464.
Li L, Keverne EB, Aparicio SA, Ishino F, Barton SC, Surani MA: Regulation of maternal behavior and offspring growth by paternally expressed Peg3. Science. 1999, 284 (5412): 330-333. 10.1126/science.284.5412.330.
Charalambous M, Smith FM, Bennett WR, Crew TE, Mackenzie F, Ward A: Disruption of the imprinted Grb10 gene leads to disproportionate overgrowth by an Igf2-independent mechanism. Proc Natl Acad Sci U S A. 2003, 100 (14): 8292-8297. 10.1073/pnas.1532175100.
Smith FM, Garfield AS, Ward A: Regulation of growth and metabolism by imprinted genes. Cytogenet Genome Res. 2006, 113 (1-4): 279-291. 10.1159/000090843.
Abu-Amero S, Monk D, Apostolidou S, Stanier P, Moore G: Imprinted genes and their role in human fetal growth. Cytogenet Genome Res. 2006, 113 (1-4): 262-270. 10.1159/000090841.
Tycko B: Imprinted genes in placental growth and obstetric disorders. Cytogenet Genome Res. 2006, 113 (1-4): 271-278. 10.1159/000090842.
Haig D, Graham C: Genomic imprinting and the strange case of the insulin-like growth factor II receptor. Cell. 1991, 64 (6): 1045-1046. 10.1016/0092-8674(91)90256-X.
Moore T, Haig D: Genomic imprinting in mammalian development: a parental tug-of-war. TIG. 1991, 7 (2): 45-49.
Mammalian Genetics Unit. [http://www.mgu.har.mrc.ac.uk/research/imprinting/function.html]
Plagge A, Isles AR, Gordon E, Humby T, Dean W, Gritsch S, Fischer-Colbrie R, Wilkinson LS, Kelsey G: Imprinted Nesp55 influences behavioral reactivity to novel environments. Mol Cell Biol. 2005, 25 (8): 3019-3026. 10.1128/MCB.25.8.3019-3026.2005.
Plagge A, Gordon E, Dean W, Boiani R, Cinti S, Peters J, Kelsey G: The imprinted signaling protein XL alpha s is required for postnatal adaptation to feeding. Nat Genet. 2004, 36 (8): 818-826. 10.1038/ng1397.
Miura K, Kishino T, Li E, Webber H, Dikkes P, Holmes GL, Wagstaff J: Neurobehavioral and electroencephalographic abnormalities in Ube3a maternal-deficient mice. Neurobiol Dis. 2002, 9 (2): 149-159. 10.1006/nbdi.2001.0463.
Brambilla R, Gnesutta N, Minichiello L, White G, Roylance AJ, Herron CE, Ramsey M, Wolfer DP, Cestari V, Rossi-Arnaud C, Grant SG, Chapman PF, Lipp HP, Sturani E, Klein R: A role for the Ras signalling pathway in synaptic transmission and long- term memory. Nature. 1997, 390 (6657): 281-286. 10.1038/36849.
Davies W, Isles A, Smith R, Karunadasa D, Burrmann D, Humby T, Ojarikre O, Biggin C, Skuse D, Burgoyne P, Wilkinson L: Xlr3b is a new imprinted candidate for X-linked parent-of-origin effects on cognitive function in mice. Nat Genet. 2005, 37 (6): 625-629. 10.1038/ng1577.
Cattanach BM, Kirk M: Differential activity of maternally and paternally derived chromosome regions in mice. Nature. 1985, 315 (6019): 496-498. 10.1038/315496a0.
Cattanach BM, Beechey CV, Peters J: Interactions between imprinting effects in the mouse. Genetics. 2004, 168 (1): 397-413. 10.1534/genetics.104.030064.
Ferguson-Smith AC, Cattanach BM, Barton SC, Beechey CV, Surani MA: Molecular and embryological investigations of parental imprinting on mouse chromosome 7. Nature. 1991, 351: 667-670. 10.1038/351667a0.
Wutz A, Theussl HC, Dausman J, Jaenisch R, Barlow DP, Wagner EF: Non-imprinted Igf2r expression decreases growth and rescues the Tme mutation in mice. Development. 2001, 128 (10): 1881-1887.
Thorvaldsen JL, Duran KL, Bartolomei MS: Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes Dev. 1998, 12 (23): 3693-3702.
Fitzpatrick GV, Soloway PD, Higgins MJ: Regional loss of imprinting and growth deficiency in mice with a targeted deletion of KvDMR1. Nat Genet. 2002, 32 (3): 426-431. 10.1038/ng988.
Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, Nowak NJ, Joyner A, Leblanc G, Hatten ME, Heintz N: A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature. 2003, 425 (6961): 917-925. 10.1038/nature02033.
Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ: p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995, 9 (6): 650-662.
Lee MH, Reynisdottir I, Massague J: Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 1995, 9 (6): 639-649.
Hatada I, Mukai T: Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat Genet. 1995, 11 (2): 204-206. 10.1038/ng1095-204.
Matsuoka S, Thompson JS, Edwards MC, Bartletta JM, Grundy P, Kalikin LM, Harper JW, Elledge SJ, Feinberg AP: Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci U S A. 1996, 93 (7): 3026-3030. 10.1073/pnas.93.7.3026.
Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ: Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature. 1997, 387 (6629): 151-158. 10.1038/387151a0.
Yan Y, Frisen J, Lee MH, Massague J, Barbacid M: Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 1997, 11 (8): 973-983.
Hatada I, Nabetani A, Morisaki H, Xin Z, Ohishi S, Tonoki H, Niikawa N, Inoue M, Komoto Y, Okada A, Steichen E, Ohashi H, Fukushima Y, Nakayama M, Mukai T: New p57KIP2 mutations in Beckwith-Wiedemann syndrome. Hum Genet. 1997, 100 (5-6): 681-683. 10.1007/s004390050573.
Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, Okada A, Ohishi S, Nabetani A, Morisaki H, Nakayama M, Niikawa N, Mukai TH, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, Okada A, Ohishi S, Nabetani A, Morisaki H, Nakayama M, Niikawa N, Mukai T: An imprinted gene p57(KIP2) is mutated in Beckwith-Wiedemann syndrome. Nat Genet. 1996, 14 (2): 171-173. 10.1038/ng1096-171.
Lee MP, DeBaun M, Randhawa G, Reichard BA, Elledge SJ, Feinberg AP: Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. Am J Hum Genet. 1997, 61 (2): 304-309.
O'Keefe D, Dao D, Zhao L, Sanderson R, Warburton D, Weiss L, Anyane-Yeboa K, Tycko B: Coding mutations in p57KIP2 are present in some cases of Beckwith- Wiedemann syndrome but are rare or absent in Wilms tumors. Am J Hum Genet. 1997, 61 (2): 295-303.
Engel JR, Smallwood A, Harper A, Higgins MJ, Oshimura M, Reik W, Schofield PN, Maher ER: Epigenotype-phenotype correlations in beckwith-wiedemann syndrome. J Med Genet. 2000, 37 (12): 921-926. 10.1136/jmg.37.12.921.
Dyer MA, Cepko CL: p57(Kip2) regulates progenitor cell proliferation and amacrine interneuron development in the mouse retina. Development. 2000, 127 (16): 3593-3605.
Joseph B, Wallen-Mackenzie A, Benoit G, Murata T, Joodmardi E, Okret S, Perlmann T: p57(Kip2) cooperates with Nurr1 in developing dopamine cells. Proc Natl Acad Sci U S A. 2003, 100 (26): 15619-15624. 10.1073/pnas.2635658100.
Feinberg AP: The two-domain hypothesis in Beckwith-Wiedemann syndrome. J Clin Invest. 2000, 106 (6): 739-740.
Caspary T, Cleary MA, Perlman EJ, Zhang P, Elledge SJ, Tilghman SM: Oppositely imprinted genes p57(Kip2) and igf2 interact in a mouse model for Beckwith-Wiedemann syndrome. Genes Dev. 1999, 13 (23): 3115-3124. 10.1101/gad.13.23.3115.
Cerrato F, Sparago A, Di Matteo I, Zou X, Dean W, Sasaki H, Smith P, Genesio R, Bruggemann M, Reik W, Riccio A: The two-domain hypothesis in Beckwith-Wiedemann syndrome: autonomous imprinting of the telomeric domain of the distal chromosome 7 cluster. Hum Mol Genet. 2005, 14 (4): 503-511. 10.1093/hmg/ddi047.
John RM, Hodges M, Little P, Barton SC, Surani MA: A human p57(KIP2) transgene is not activated by passage through the maternal mouse germline. Hum Mol Genet. 1999, 8 (12): 2211-2219. 10.1093/hmg/8.12.2211.
John RM, Ainscough JF, Barton SC, Surani MA: Distant cis-elements regulate imprinted expression of the mouse p57( Kip2) (Cdkn1c) gene: implications for the human disorder, Beckwith--Wiedemann syndrome. Hum Mol Genet. 2001, 10 (15): 1601-1609. 10.1093/hmg/10.15.1601.
Takahashi K, Nakayama K, Nakayama K: Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal abnormalities and growth retardation. J Biochem (Tokyo). 2000, 127 (1): 73-83.
Qian N, Frank D, O'Keefe D, Dao D, Zhao L, Yuan L, Wang Q, Keating M, Walsh C, Tycko B: The IPL gene on chromosome 11p15.5 is imprinted in humans and mice and is similar to TDAG51, implicated in Fas expression and apoptosis. Hum Mol Genet. 1997, 6 (12): 2021-2029. 10.1093/hmg/6.12.2021.
Dao D, Frank D, Qian N, O'Keefe D, Vosatka RJ, Walsh CP, Tycko B: IMPT1, an imprinted gene similar to polyspecific transporter and multi-drug resistance genes. Hum Mol Genet. 1998, 7 (4): 597-608. 10.1093/hmg/7.4.597.
Salas M, John R, Saxena A, Barton S, Frank D, Fitzpatrick G, Higgins MJ, Tycko B: Placental growth retardation due to loss of imprinting of Phlda2. Mech Dev. 2004, 121 (10): 1199-1210. 10.1016/j.mod.2004.05.017.
Constancia M, Hemberger M, Hughes J, Dean W, Ferguson-Smith A, Fundele R, Stewart F, Kelsey G, Fowden A, Sibley C, Reik W: Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature. 2002, 417 (6892): 945-948. 10.1038/nature00819.
Bondy C, Werner H, Roberts CT, LeRoith D: Cellular pattern of type-I insulin-like growth factor receptor gene expression during maturation of the rat brain: comparison with insulin-like growth factors I and II. Neuroscience. 1992, 46 (4): 909-923. 10.1016/0306-4522(92)90193-6.
D'Ercole AJ, Ye P, Calikoglu AS, Gutierrez-Ospina G: The role of the insulin-like growth factors in the central nervous system. Mol Neurobiol. 1996, 13 (3): 227-255.
Duvillie B, Cordonnier N, Deltour L, Dandoy-Dron F, Itier JM, Monthioux E, Jami J, Joshi RL, Bucchini D: Phenotypic alterations in insulin-deficient mutant mice. Proc Natl Acad Sci U S A. 1997, 94 (10): 5137-5140. 10.1073/pnas.94.10.5137.
Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993, 75 (1): 59-72.
Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, Gillett N, Stewart TA: IGF-I is required for normal embryonic growth in mice. Genes Dev. 1993, 7 (12B): 2609-2617.
Forne T, Oswald J, Dean W, Saam JR, Bailleul B, Dandolo L, Tilghman SM, Walter J, Reik W: Loss of the maternal H19 gene induces changes in Igf2 methylation in both cis and trans. Proc Natl Acad Sci U S A. 1997, 94 (19): 10243-10248. 10.1073/pnas.94.19.10243.
Schonherr N, Meyer E, Roos A, Schmidt A, Wollmann HA, Eggermann T: The centromeric 11p15 imprinting centre is also involved in Silver-Russell syndrome. J Med Genet. 2007, 44 (1): 59-63. 10.1136/jmg.2006.044370.
Doyle P, Beral V, Maconochie N: Preterm delivery, low birthweight and small-for-gestational-age in liveborn singleton babies resulting from in-vitro fertilization. Hum Reprod. 1992, 7 (3): 425-428.
Buitendijk SE: Children after in vitro fertilization. An overview of the literature. Int J Technol Assess Health Care. 1999, 15 (1): 52-65. 10.1017/S0266462399015160.
Schieve LA, Meikle SF, Ferre C, Peterson HB, Jeng G, Wilcox LS: Low and very low birth weight in infants conceived with use of assisted reproductive technology. N Engl J Med. 2002, 346 (10): 731-737. 10.1056/NEJMoa010806.
DeBaun MR, Niemitz EL, Feinberg AP: Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. Am J Hum Genet. 2003, 72 (1): 156-160. 10.1086/346031.
Maher ER, Afnan M, Barratt CL: Epigenetic risks related to assisted reproductive technologies: epigenetics, imprinting, ART and icebergs?. Hum Reprod. 2003, 18 (12): 2508-2511. 10.1093/humrep/deg486.
Maher ER, Brueton LA, Bowdin SC, Luharia A, Cooper W, Cole TR, Macdonald F, Sampson JR, Barratt CL, Reik W, Hawkins MM: Beckwith-Wiedemann syndrome and assisted reproduction technology (ART). J Med Genet. 2003, 40 (1): 62-64. 10.1136/jmg.40.1.62.
Maher ER: Imprinting and assisted reproductive technology. Hum Mol Genet. 2005, 14 Spec No 1: R133-8. 10.1093/hmg/ddi107.
O'Neill MJ, Ingram RS, Vrana PB, Tilghman SM: Allelic expression of IGF2 in marsupials and birds. Dev Genes Evol. 2000, 210 (1): 18-20. 10.1007/PL00008182.
Killian JK, Nolan CM, Stewart N, Munday BL, Andersen NA, Nicol S, Jirtle RL: Monotreme IGF2 expression and ancestral origin of genomic imprinting. J Exp Zool. 2001, 291 (2): 205-212. 10.1002/jez.1070.
John RM, Surani MA: Genomic imprinting, mammalian evolution, and the mystery of egg-laying mammals. Cell. 2000, 101 (6): 585-588. 10.1016/S0092-8674(00)80870-3.
Suzuki S, Renfree MB, Pask AJ, Shaw G, Kobayashi S, Kohda T, Kaneko-Ishino T, Ishino F: Genomic imprinting of IGF2, p57(KIP2) and PEG1/MEST in a marsupial, the tammar wallaby. Mech Dev. 2005, 122 (2): 213-222. 10.1016/j.mod.2004.10.003.
John RM: A transgenic approach to studying imprinted genes: Modified BACs and PACs. Methods in Molecular Biology. Edited by: Ward A. 2002, Totowa, New Jersey , Humana Press, 181: 67-82.
John RM, Aparicio SA, Ainscough JF, Arney KL, Khosla S, Hawker K, Hilton KJ, Barton SC, Surani MA: Imprinted expression of neuronatin from modified BAC transgenes reveals regulation by distinct and distant enhancers. Dev Biol. 2001, 236 (2): 387-399. 10.1006/dbio.2001.0327.
Hogan B, Beddington R, Constantini. F, Lacy E: Manipulating the mouse embryo: a laboratory manual. 1994, Cold Spring Harbor , Cold Spring Harbor Laboratory Press, Second Edition
Primer 3 website. [http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi]
Ogawa H, Ono Y, Shimozawa N, Sotomaru Y, Katsuzawa Y, Hiura H, Ito M, Kono T: Disruption of imprinting in cloned mouse fetuses from embryonic stem cells. Reproduction. 2003, 126 (4): 549-557. 10.1530/rep.0.1260549.
Wu Q, Ohsako S, Ishimura R, Suzuki JS, Tohyama C: Exposure of mouse preimplantation embryos to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) alters the methylation status of imprinted genes H19 and Igf2. Biol Reprod. 2004, 70 (6): 1790-1797. 10.1095/biolreprod.103.025387.
This work was supported by The Wellcome Trust grant 074851. MDW is a BBSRC PhD student and SJT is a MRC PhD student. The authors would like to thank Dr Andrew Ward and Dr Nick Allen for their insightful comments.
RMJ was the major contributor to conception and design, acquisition of data, analysis and interpretation of data and generated the Cdkn1c transgenic lines in the study and drafted the manuscript. MAS contributed to conception and design. SCB generated the control transgenic line and participated in the initial characterisations. SCA was involved in the acquisition of data, analysis and interpretation of data. MDW designed and implemented qRT-PCR studies while SJT dissected animals for data and managed the transgenic colonies.
All authors read and approved the final manuscript.
About this article
Cite this article
Andrews, S.C., Wood, M.D., Tunster, S.J. et al. Cdkn1c (p57Kip2) is the major regulator of embryonic growth within its imprinted domain on mouse distal chromosome 7. BMC Dev Biol 7, 53 (2007). https://doi.org/10.1186/1471-213X-7-53